HROW entered its Q1 print as one of the most shorted small-cap pharma names on Nasdaq. The stock's 24% collapse confirms that heavy positioning wasn't misplaced.
Harrow reported Q1 results after the close on May 11. EPS missed by $0.39 — a 39-cent gap that spooked a market already braced for disappointment. The stock fell 24% over two sessions to close at $29.03, wiping out the gains of the past two months. The company reaffirmed its full-year 2026 revenue guidance of $350M–$365M and guided Q2 revenue of $71M–$81M, bracketing the prior consensus of $76.6M. That wide Q2 band did little to calm sellers. A securities-law investigation notice filed on May 13 added a fresh layer of headline risk.
Short sellers had been building this position steadily for months. SI % of free float climbed from roughly 21% in early March to 23.8% by May 12 — a base that had barely budged in weeks, suggesting the bears were already fully loaded before the earnings release. Days to cover runs at nearly 12 days on FINRA data, meaning any meaningful covering rally would take time to clear. The borrow market is tighter than it looks: availability has been in the low-to-mid range for weeks, and borrowing costs ticked up 11% over the past week to 0.84% APR, the firmest level since late April. That's still a manageable cost, but the direction is clear — lenders are growing more selective.
The Street hasn't panicked into sells. Every firm on record maintains a Buy or Overweight rating. Cantor Fitzgerald, reacting to the print, trimmed its target from $91 to $88 while holding Overweight. BTIG reiterated Buy at $63. The mean price target across analysts sits at $68.13 — more than double the current $29.03 print. That gap is striking, but it reflects analyst targets set pre-crash rather than a fresh bull conviction. The most important factor scores are also worth noting: HROW's ORTEX short score has been running at 78–80 for weeks, ranking in roughly the 4th percentile for short-interest pressure across the universe. EPS surprise scores, however, rank in the 91st percentile historically — which makes a 39-cent miss all the more jarring for holders who expected the company to beat.
The ownership structure adds a dimension bears will watch. Opaleye Management, the largest institutional holder at nearly 10% of shares, sold over 198,000 shares between late February and early March — offloading stock in the high $30s and low $50s before this week's plunge. That selling predated the earnings miss but coincided with the stock trading well above current levels. CEO and Founder Mark Baum also sold roughly 80,000 shares in December at $47. With these notable insiders having lightened up, there is less of a natural "buy the dip" anchor from the top of the register than might otherwise exist.
Options sentiment is notably call-heavy. The put/call ratio has barely moved this week at 0.23, well below the 52-week high of 0.49. That's the opposite of what you'd expect if the broader options market was rushing to hedge a broken stock — it suggests the options book remains dominated by call holders who have not yet rotated into protection. Whether that reflects lingering upside conviction or simply a lack of activity in a thinly traded options market is the key question to track as the week closes out.
The next data point to watch is whether short sellers continue adding after the print, or whether 23.8% of float proves a ceiling. Availability remains the binding constraint in either direction.
See the live data behind this article on ORTEX.
Open HROW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
